Skip to Content

Kymriah Approval History

FDA Approved: Yes (First approved August 30, 2017)
Brand name: Kymriah
Generic name: tisagenlecleucel
Dosage form: Suspension for Intravenous Infusion
Previous Name: CTL019
Company: Novartis Pharmaceuticals Corporation
Treatment for: Acute Lymphoblastic Leukemia; Large B-Cell Lymphoma

Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for use in patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and patients with relapsed or refractory (r/r) large B-cell lymphoma.

Development History and FDA Approval Process for Kymriah

May  1, 2018Approval Kymriah (tisagenlecleucel) Receives Second FDA Approval to Treat Appropriate Patients with Large B-Cell Lymphoma
Dec 10, 2017Primary Analysis Results from Novartis Pivotal JULIET Trial Show Kymriah (tisagenlecleucel) Sustained Complete Responses at Six Months in Adults with r/r DLBCL, a Difficult-to-Treat Cancer
Aug 30, 2017Approval FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia
Jul 12, 2017Novartis CAR-T Cell Therapy CTL019 Unanimously (10-0) Recommended for Approval by FDA Advisory Committee to Treat Pediatric, Young Adult r/r B-Cell ALL
Apr 18, 2017Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Adult Patients with r/r DLBCL
Mar 29, 2017Novartis Announces First CAR-T Cell Therapy BLA for Pediatric and Young Adult Patients with r/r B-Cell ALL Granted FDA Priority Review
Dec  4, 2016Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
Jun  1, 2015Novartis Highlights CTL019 Data in the Treatment of Specific Types of Hard-to-Treat non-Hodgkin Lymphoma
Dec  6, 2014Novartis Highlights New CTL019 Clinical Data Showing Complete Remissions in Relapsed/Refractory Acute Lymphoblastic Leukemia
Jul  7, 2014Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.